公开(公告)号：US09546401B2

公开(公告)日：2017-01-17

申请号：US13796362

申请日：2013-03-12

申请人： The General Hospital Corporation ,  NESTLE HEALTH SCIENCE—PAMLAB, INC.

发明人： Maurizio Fava ,  George Papakostas ,  Harold O. Koch, Jr. ,  David Kronlage

IPC分类号： C12Q1/68 ,  C12P19/34 ,  A61K31/714

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52

摘要： Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, 4-HNE, and/or hsCRP) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating at least one symptom (e.g., at least one core symptom) of depression in a subject and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

摘要翻译： 本文公开了用于通过鉴定至少一种核酸多态性（例如但不限于在MTHFR，MTR或MTRR基因座）和/或确定表达的方法来选择具有抑郁症的受试者的治疗方案的新型测定，系统和试剂盒 来自人类受试者的测试样品中的外周生物标志物（例如，SAM，SAH，4-HNE和/或hsCRP）的水平。 这些生物标志物可用于确定用含叶酸化合物（单独或作为抗抑郁药的辅助物）治疗抑郁受试者的有效性。 此外，这些生物标志物可用于为具有治疗抗性抑郁症（例如对至少一种选择性5-羟色胺再摄取抑制剂的抗性）的受试者选择适当的治疗方案。 本文还提供了用于治疗受试者中抑郁症的至少一种症状（例如至少一种核心症状）和/或确定或改善受试者服用的抗抑郁药物的有效性的方法和组合物。

公开(公告)号：US09540691B2

公开(公告)日：2017-01-10

申请号：US13789075

申请日：2013-03-07

申请人： THE GENERAL HOSPITAL CORPORATION ,  NESTLE HEALTH SCIENCE-PAMLAB, INC.

发明人： Maurizio Fava ,  George Papakostas ,  Harold O. Koch, Jr. ,  David Kronlage

IPC分类号： C12Q1/68 ,  C12P19/34 ,  A61K31/714

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52

摘要： Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, and 4-HNE) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating a subject with depression and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

摘要翻译： 本文公开了用于通过鉴定至少一种核酸多态性（例如但不限于在MTHFR，MTR或MTRR基因座）和/或确定表达的方法来选择具有抑郁症的受试者的治疗方案的新型测定，系统和试剂盒 来自人类受试者的测试样品中的外周生物标志物（例如，SAM，SAH和4-HNE）的水平。 这些生物标志物可用于确定用含叶酸化合物（单独或作为抗抑郁药的辅助物）治疗抑郁受试者的有效性。 此外，这些生物标志物可用于为具有治疗抗性抑郁症（例如对至少一种选择性5-羟色胺再摄取抑制剂的抗性）的受试者选择适当的治疗方案。 本文还提供了用于治疗患有抑郁症的受试者和/或确定或改善受试者服用的抗抑郁药物的有效性的方法和组合物。

公开(公告)号：US20130267523A1

公开(公告)日：2013-10-10

申请号：US13796362

申请日：2013-03-12

申请人： PAMLAB, L.L.C. ,  THE GENERAL HOSPITAL CORPORATION

发明人： Maurizio Fava ,  George Papakostas ,  Harold O. Koch, Jr. ,  David Kronlage

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52

摘要： Disclosed herein are novel assays, systems and kits for selecting a treatment regimen for a subject with depression by identifying at least one nucleic acid polymorphism, e.g., but not limited to, at the MTHFR, MTR, or MTRR locus, and/or determining expression levels of peripheral biomarkers (e.g., SAM, SAH, 4-HNE, and/or hsCRP) in a test sample from a human subject. These biomarkers can be used to determine the effectiveness of treating a depressed subject with a folate-containing compound (alone or as an adjunct to an antidepressant). Additionally, these biomarkers can be used to select an appropriate treatment regimen for subjects with treatment-resistant depression (e.g., resistant to at least one selective serotonin reuptake inhibitor). Methods and compositions for treating at least one symptom (e.g., at least one core symptom) of depression in a subject and/or determining or improving the effectiveness of an antidepressant drug taken by a subject are also provided herein.

摘要翻译： 本文公开了用于通过鉴定至少一种核酸多态性（例如但不限于在MTHFR，MTR或MTRR基因座）和/或确定表达的方法来选择具有抑郁症的受试者的治疗方案的新型测定，系统和试剂盒 来自人类受试者的测试样品中的外周生物标志物（例如，SAM，SAH，4-HNE和/或hsCRP）的水平。 这些生物标志物可用于确定用含叶酸化合物（单独或作为抗抑郁药的辅助物）治疗抑郁受试者的有效性。 此外，这些生物标志物可用于为具有治疗抗性抑郁症（例如对至少一种选择性5-羟色胺再摄取抑制剂的抗性）的受试者选择适当的治疗方案。 本文还提供了用于治疗受试者中抑郁症的至少一种症状（例如至少一种核心症状）和/或确定或改善受试者服用的抗抑郁药物的有效性的方法和组合物。